Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.64 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917618 | 1.00 | LPAR1 (0.64) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23907345 | 0.90 | LPAR1 (0.61) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23907346 | 0.90 | LPAR1 (0.61) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23917617 | 0.84 | LPAR1 (0.45) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23907370 | 0.84 | LPAR1 (0.53) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23907368 | 0.84 | LPAR1 (0.53) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL21806657 | 0.82 | LPAR1 (0.42) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL16556435 | 0.80 | LPAR1 (0.58) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL23917613 | 0.79 | LPAR1 (0.66) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL30197491 | 0.79 | LPAR1 (0.66) | LPAR1LPAR3LPAR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |